Characteristic Effects of .ALPHA.1-.BETA.1,2-Adrenergic Blocking Agent, Carvedilol, on [Ca2+]i in Ventricular Myocytes Compared With Those of Timolol and Atenolol.
- 1 January 2003
- journal article
- research article
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 67 (1), 83-90
- https://doi.org/10.1253/circj.67.83
Abstract
Beta-adrenergic stimulation and the resultant Ca2+ load both seem to be associated with progression of heart failure as well as hypertrophy. Because the α1-, β1,2-blocker, carvedilol, has been shown to be outstandingly beneficial in the treatment of heart failure, its direct effects on intracellular calcium ion concentration ([Ca2+]i), including antagonism to isoproterenol, in ventricular myocytes were investigated and then comapred with a selective β1-blocker, atenolol, and a non-selective β1,2-blocker, timolol. At 1-300 nmol/L, carvedilol decreased the amplitude of [Ca2+] i by ~20% independently of its concentration, which was a similar effect to timolol. All the β-blockers at 10 nmol/L decreased the amount of cAMP, but atenolol had the least effect. Carvedilol in the μmol/L order further diminished the amplitude of [Ca2+]i transients, and at 10 μmol/L increased the voltage threshold for pacing myocytes. These effects were not observed with timolol or atenolol. L-type Ca2+ currents (ICa) were decreased by carvedilol in the μmol/L order in a concentration dependent manner. As for the β-antagonizing effect, the concentrations of carvedilol, timolol, and atenolol needed to prevent the effect of isoproterenol by 50% (IC50) were 1.32, 2.01, and 612 nmol/L, respectively. Furthermore, the antagonizing effect of carvedilol was dramatically sustained even after removal of the drug from the perfusate. Carvedilol exerts negative effects on [Ca2+]i, including inhibition of the intrinsic β-activity, reduction of ICa in the μmol/L order, and an increase in the threshold for pacing at ≥10 μmol/L. Data on the IC50 for the isoproterenol effect suggest that carvedilol could effectively inhibit the [Ca2+]i load induced by catecholamines under clinical conditions. (Circ J 2003; 67: 83 - 90)Keywords
This publication has 25 references indexed in Scilit:
- Discrete Microdomains with High Concentration of cAMP in Stimulated Rat Neonatal Cardiac MyocytesScience, 2002
- PKA Phosphorylation Dissociates FKBP12.6 from the Calcium Release Channel (Ryanodine Receptor)Cell, 2000
- Complications Associated with Rapid Caffeine Application to Cardiac Myocytes that are not Voltage ClampedJournal of Molecular and Cellular Cardiology, 1998
- The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart FailureNew England Journal of Medicine, 1996
- Immediate-early gene induction and MAP kinase activation during recovery from metabolic inhibition in cultured cardiac myocytes.Journal of Clinical Investigation, 1995
- Clinical Pharmacokinetics and Pharmacodynamics of CarvedilolClinical Pharmacokinetics, 1994
- Reverse intrinsic activity of antagonists on G protein-coupled receptorsTrends in Pharmacological Sciences, 1992
- Calcium antagonist cautionThe Lancet, 1991
- In vitro Pharmacologic Profile of the Novel Beta-Adrenoceptor Antagonist and Vasodilator, CarvedilolPharmacology, 1989
- Atenolol Dose-Finding StudiesDrugs, 1983